DomainexDomainex was established in 2002 as a spin out company from The Institute of Cancer Research, UCL and Birkbeck College.

Domainex combines internal drug discovery programmes with a profitable contract research business. Both strands of the business leverage Domainex’s proprietary technology platforms; ‘Combinatorial Domain Hunting’ (CDH) and Leadbuilder:

(1) CDH is a revolutionary technique for cloning and expressing drug targets - a significant bottleneck in the drug discovery process; and .

(2) Leadbuilder is a proprietary database of chemical structures - allows small biotechnology companies to achieve the same high throughput screening power as large pharmaceutical companies.

Potential new targets for drug discovery and vaccine development can be found from available genomic information but exploring these targets requires the identification of soluble and expressible protein domains

Potential new drugs can be discovered by screening them against proteins. However in order to achieve this, the protein must be generated in large amounts and, critically, it must be provided in a soluble form. If a protein cannot be produced in its full length, a similar result can be achieved with its ‘domains’ provided they can be isolated in a soluble form.

Domainex developed CDH to discover the soluble domains of proteins in a rapid and cost effective manner.

For more information on Domainex please click here.